Latest News about Benzinga
Recent news which mentions Benzinga
Peeling Back The Layers: Exploring Dave Through Analyst Insights
September 10, 2024
Tickers
DAVE
From Benzinga
Here's How Much $1000 Invested In Guidewire Software 10 Years Ago Would Be Worth Today
September 10, 2024
From Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,000 Today
September 10, 2024
From Benzinga
How Is The Market Feeling About First American Financial?
September 10, 2024
Tickers
FAF
From Benzinga
Tradepulse Power Inflow Alert: Service Now Inc. Moves Up Over 2% After Alert On The Trading Day
September 10, 2024
Tickers
NOW
From Benzinga
Newsom Rejects Bill To Aid Migrants With Home Loans–Here's Why
September 10, 2024
From Benzinga
Bill Gates' Efforts To Eradicate Malaria And The Economic Impact Of Ridding The Globe Of This Disease
September 10, 2024
From Benzinga
US Stocks Mixed; Oracle Posts Upbeat Results
September 10, 2024
From Benzinga
GOP Lawmaker Defends Google Amid Antitrust Trial: 'Penalize Them For Trying To Be Good Business? That's Insane'
September 10, 2024
From Benzinga
AST SpaceMobile Options Trading: A Deep Dive into Market Sentiment
September 10, 2024
Tickers
ASTS
From Benzinga
Spotlight on MicroStrategy: Analyzing the Surge in Options Activity
September 10, 2024
Tickers
MSTR
From Benzinga
What's Going On With XPeng Stock Today?
September 10, 2024
From Benzinga
Walmart's Stock Mirrors Its Late 90s Explosion With A Recent 46% Year-to-Date Surge Unveiling New Highs And Promising Breakthroughs Beyond $100
September 10, 2024
Tickers
WMT
From Benzinga
Bitcoin Back To $57K, But Monday's ETF Inflows Don't Drag It Out Of Bearish Territory, Analysts Say
September 10, 2024
From Benzinga
Why Is Under Armour Stock Sliding Today?
September 10, 2024
From Benzinga
EXCLUSIVE: Lazard Small-Cap Expert Predicts 30-50% Russell 2000 Rally On The Back Of Lower Interest Rates
September 10, 2024
From Benzinga
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
September 10, 2024
From Benzinga
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
September 10, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.